Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06989359RecruitingPhase 2
Study of ADX-038 for complement-related kidney disease
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
Doral, FloridaAges 18 years+ - NCT06858319RecruitingPhase 3
Long-term study of zigakibart for IgA nephropathy
This study is for people with IgA nephropathy who completed a previous zigakibart study. It tests whether continuing treatment with zigakibart (given as a shot every two weeks) is safe and helpful over a longer period.
Denver, ColoradoAges 18–100 - NCT03512132Recruiting
Test HDL function in type 1 diabetes with kidney changes
This study looks at how well “good cholesterol” (HDL) works in people with type 1 diabetes, especially when kidney tests show early or more advanced damage. Researchers will compare different groups (normal, micro-, and macro-albumin in urine) to better understand HDL’s role and how it may relate to kidney health.
DijonAges 18 years+ - NCT03865914Recruiting
Study linking diabetes kidney findings to biopsy results
This study looks at people with type 2 diabetes who have kidney problems and relates their symptoms and lab findings to what is seen on kidney biopsy. It may help doctors better understand what is driving kidney damage in diabetes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04196244RecruitingPhase 4
IV-contrast CT vs no-contrast CT for urgent abdominal pain
This study compares two types of CT scans—using IV contrast dye versus not using dye—in people who need an emergency abdominal scan but have reduced kidney function. It aims to see which approach is safer and works well enough to help doctors find the cause.
EspooAges 18 years+ - NCT04207437Recruiting
Daily handheld vibration therapy for chemotherapy nerve pain
This trial studies whether daily handheld vibration can lessen nerve damage symptoms in the hands after certain chemotherapy medicines. It may help reduce numbness, tingling, or pain from chemotherapy-related nerve problems.
Avon, IndianaAges 18 years+ - NCT04279457RecruitingPhase 4
Test whether special dye helps protect kidney function during heart procedures
This trial studies whether a device called Dye-Vert Plus can lower the risk of kidney injury from contrast dye during heart catheter procedures (CAG and/or PCI). It focuses on people at higher kidney risk, especially those with diabetes or high blood pressure.
Charleston, West VirginiaAges 18–90 - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Atlanta, GeorgiaAges 1–80 - NCT04745728RecruitingPhase 3
Testing different immune-suppressing treatments for membranous kidney disease
This Phase 3 trial compares different immune-suppressing medicines for idiopathic membranous nephropathy (a kidney disease caused by the immune system). It may help reduce heavy protein leakage in the urine and improve disease control in people who fit specific prior-treatment and lab requirements.
Beijing, Beijing MunicipalityAges 18–80 - NCT04982419RecruitingPhase 2/Phase 3
Remote arm treatment to protect heart and kidneys in heart failure
This trial tests whether a simple “arm cuff” treatment done before a heart artery procedure can help protect the kidneys and the heart in people with congestive heart failure. If it works, it may lower the chance of kidney injury around the time of the scan/stent procedure.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05003986RecruitingPhase 2
Sparsentan for children with protein leaking kidney diseases
This Phase 2 study tests sparsentan in children with certain kidney diseases that cause high amounts of protein in the urine. It aims to see if the medicine can reduce kidney damage signals and protein leakage compared with standard care.
Los Angeles, CaliforniaAges 1–17 - NCT05283512Recruiting
IV versus drink fluids to protect kidneys after CT scan
This study compares giving fluids through a vein versus drinking fluids to lower the risk of sudden kidney injury after a CT scan with contrast dye. It focuses on adults with very poor kidney function who are scheduled for an elective CT scan.
Odense C, FynAges 18 years+ - NCT05510323RecruitingPhase 3
Immunosuppressive treatment for IgA kidney disease in stage 3–4
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
Xi'anAges 18 years+ - NCT05656261Recruiting
Genetic testing study for African Americans
This study looks at genetic markers (genes) related to kidney risk in Black/African American adults. It may help researchers better understand who is at higher risk and how genetics could guide future care.
St Louis, MissouriAges 18–90 - NCT05692388Recruiting
Study social needs support for Black adults with kidney and diabetes
This study looks at health-related social needs—like barriers to food, housing, or care—in African American adults living with type 2 diabetes and chronic kidney disease. It uses a mixed-methods approach to understand needs better and what support may help.
Milwaukee, WisconsinAges 18 years+ - NCT05791162Recruiting
Looking at immune cell ratios in IgA kidney disease
This study looks at how certain immune cells in blood relate to IgA nephropathy, a kidney condition. It may help doctors understand which patients are likely to do better and guide future care.
BesançonAges 18 years+ - NCT05942625RecruitingPhase 1
Study of an experimental drug in healthy adults
This Phase 1 trial tests how safe and tolerable an experimental medicine (HS-10390) is in healthy adults, and how the body processes it. It is not for people with an illness, but for healthy volunteers to help researchers understand the drug before future studies.
Nanjing, JiangsuAges 18–45 - NCT05975671Recruiting
Survey in pediatric ICU to reduce upfront vancomycin use
This study is a survey and quality-improvement effort in participating children’s intensive care units. It aims to understand and change how doctors decide to start vancomycin (an antibiotic) when sepsis is suspected, to improve care and avoid unnecessary use.
Atlanta, GeorgiaAges Any age - NCT06217302RecruitingPhase 3
Sotagliflozin for kidney protection in type 1 diabetes
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
Stanford, CaliforniaAges 18–75 - NCT06325059Recruiting
Kidney cell study for glomerular and tubular diseases
This trial studies kidney biopsy samples to learn how certain kidney cells repair damage. It may help find new treatments for kidney diseases.
FlorenceAges 1 month–17 years - NCT06416761Recruiting
Genetics and kidney disease progression study
This study looks at how genetics affect the progression of kidney diseases. Joining may help researchers understand your condition better and find better treatments.
MilanAges 18 years+ - NCT06557265RecruitingPhase 1/Phase 2
NKX019 for lupus kidney disease or membranous nephropathy
This trial tests an experimental cell therapy called NKX019 for people with active lupus nephritis (a type of kidney inflammation from lupus) or primary membranous nephropathy (another kidney condition) that hasn't gotten better after standard treatments. It may help if you have tried at least two treatments for lupus kidney disease or one for membranous nephropathy and still have active kidney disease.
Little Rock, ArkansasAges 18–75 - NCT06586203Recruiting
Genomic test to guide diabetes heart and kidney care
This study is testing whether a special blood test (genomic predictor) can help doctors better manage heart and kidney risks in people with type 2 diabetes. You may benefit from learning your personal risk score and getting more tailored care.
Montreal, QuebecAges 18 years+ - NCT06654596Recruiting
Telitacicept for IgA nephropathy
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
ShanghaiAges 18–70
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 147 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.